Publicacións nas que colabora con Nieves Domenech García (21)

2024

  1. Reduced mitochondrial pyruvate carrier expression in hearts with heart failure and reduced ejection fraction patients: ischemic vs. non-ischemic origin

    Frontiers in Cardiovascular Medicine, Vol. 11

2023

  1. SERCA2a Protein Levels Are Unaltered in Human Heart Failure

    Circulation, Vol. 148, Núm. 7, pp. 613-616

  2. Soluble HLA-G levels in heart transplant recipients: Dynamics and correlation with clinical outcomes

    Transplant Immunology, Vol. 76

  3. Survival impact of previous statin therapy in patients hospitalized with COVID-19

    Medicina Clinica, Vol. 160, Núm. 1, pp. 1-9

2022

  1. Cardiac protection induced by urocortin-2 enables the regulation of apoptosis and fibrosis after ischemia and reperfusion involving miR-29a modulation

    Molecular Therapy - Nucleic Acids, Vol. 27, pp. 838-853

  2. Specialized Proresolving Mediators Protect Against Experimental Autoimmune Myocarditis by Modulating Ca2+ Handling and NRF2 Activation

    JACC: Basic to Translational Science, Vol. 7, Núm. 6, pp. 544-560

2021

  1. Extracellular Matrix in Heart Failure: Role of ADAMTS5 in Proteoglycan Remodeling

    Circulation, Vol. 144, Núm. 25, pp. 2021-2034

2020

  1. Mitochondrial pyruvate carrier abundance mediates pathological cardiac hypertrophy

    Nature Metabolism, Vol. 2, Núm. 11, pp. 1223-1231

2019

  1. Circulating Galectin-3 Following Heart Transplant: Long-term Dynamics and Prognostic Value

    Revista Espanola de Cardiologia, Vol. 72, Núm. 11, pp. 899-906

2018

  1. Comparison of the PI3K-AKT-mTOR Pathway Expression Profile in Tumoral Versus Nontumoral Tissue Samples From Heart Transplant Recipients

    Revista Espanola de Cardiologia, Vol. 71, Núm. 8, pp. 674-676

2017

  1. Role of NOD1 in Heart Failure Progression via Regulation of Ca2+ Handling

    Journal of the American College of Cardiology, Vol. 69, Núm. 4, pp. 423-433

2016

  1. Analysis of mitochondrial proteins in the surviving myocardium after ischemia identifies mitochondrial pyruvate carrier expression as possible mediator of tissue viability

    Molecular and Cellular Proteomics, Vol. 15, Núm. 1, pp. 246-255

2013

  1. Mitochondrial DNA haplogroup H as a risk factor for idiopathic dilated cardiomyopathy in Spanish population

    Mitochondrion, Vol. 13, Núm. 4, pp. 263-268

2012

  1. Indoleamine, 2-3 dioxygenase activity could be an early marker of graft rejection in heart transplantation

    Transplantation Proceedings

  2. Mitochondrial Haplogroups H and J: Risk and Protective Factors for Ischemic Cardiomyopathy

    PLoS ONE, Vol. 7, Núm. 8

  3. Proteomics analysis of cardiac extracellular matrix remodeling in a porcine model of ischemia/reperfusion injury

    Circulation, Vol. 125, Núm. 6, pp. 789-802

2009

  1. Analysis of Different Routes of Administration of Heterologous 5-Azacytidine-Treated Mesenchymal Stem Cells in a Porcine Model of Myocardial Infarction

    Transplantation Proceedings, Vol. 41, Núm. 6, pp. 2273-2275

  2. Comparison of Gene Expression Profiles in a Porcine Infarct Model After Intracoronary, Transthoracic, or Transendocardiac Injection of Heterologous Bone Marrow Mesenchymal Cells

    Transplantation Proceedings, Vol. 41, Núm. 6, pp. 2279-2281

2005

  1. Humoral heart rejection (severe allograft dysfunction with no signs of cellular rejection or ischemia): Incidence, management, and the value of C4d for diagnosis

    American Journal of Transplantation, Vol. 5, Núm. 10, pp. 2560-2564

2004

  1. Severe cardiac allograft dysfunction without endomyocardial biopsy signs of cellular rejection: Incidence and management

    Transplantation Proceedings